128 results
8-K
EX-99.1
ABBV
AbbVie Inc.
25 Jul 24
AbbVie Reports Second-Quarter 2024 Financial Results
7:41am
of Clinical Oncology (ASCO) Annual Meeting, AbbVie showcased its solid tumor pipeline with new data from its innovative antibody-drug conjugate (ADC … and Gilgamesh's innovative research platform to discover novel neuroplastogens.
Full-Year 2024 Outlook
AbbVie is raising its adjusted diluted EPS guidance
8-K
EX-99.1
ABBV
AbbVie Inc.
26 Apr 24
AbbVie Reports First-Quarter 2024 Financial Results
7:43am
and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact
8-K
EX-99.1
spbbt2j21wioaeqnu
20 Feb 24
AbbVie Announces Appointment of Robert A. Michael as Chief Executive Officer
9:00am
8-K
EX-99.1
nwyv4fss
12 Feb 24
AbbVie Completes Acquisition of ImmunoGen
7:49am
8-K
EX-99.1
3ox732xf
2 Feb 24
AbbVie Reports Full-Year and Fourth-Quarter 2023 Financial Results
7:51am
8-K
EX-99.1
gzfeny1icb4ub8w
6 Dec 23
AbbVie to Acquire Cerevel Therapeutics in Transformative Transaction to Strengthen Neuroscience Pipeline
5:28pm
8-K
EX-99.2
3nd0smbur8bdc8g
6 Dec 23
AbbVie to Acquire Cerevel Therapeutics in Transformative Transaction to Strengthen Neuroscience Pipeline
5:28pm
8-K
EX-99.1
5s0yko t88u
30 Nov 23
AbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHERE® (mirvetuximab soravtansine-gynx), Expanding Solid Tumor Portfolio
8:47am
8-K
EX-99.1
aar2v6ez
27 Oct 23
AbbVie Reports Third-Quarter 2023 Financial Results
7:49am
8-K
EX-99.1
dgu9xaimdcng
27 Jul 23
AbbVie Reports Second-Quarter 2023 Financial Results
7:45am
8-K
EX-99.1
vqey81p
27 Apr 23
AbbVie Reports First-Quarter 2023 Financial Results
7:36am